JP2008543967A - 炎症性皮膚病変を治療するためのスーパーオキシドジスムターゼとカタラーゼとの混合物の使用 - Google Patents
炎症性皮膚病変を治療するためのスーパーオキシドジスムターゼとカタラーゼとの混合物の使用 Download PDFInfo
- Publication number
- JP2008543967A JP2008543967A JP2008518988A JP2008518988A JP2008543967A JP 2008543967 A JP2008543967 A JP 2008543967A JP 2008518988 A JP2008518988 A JP 2008518988A JP 2008518988 A JP2008518988 A JP 2008518988A JP 2008543967 A JP2008543967 A JP 2008543967A
- Authority
- JP
- Japan
- Prior art keywords
- use according
- superoxide dismutase
- catalase
- mixture
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000019197 Superoxide Dismutase Human genes 0.000 title claims abstract description 65
- 108010012715 Superoxide dismutase Proteins 0.000 title claims abstract description 65
- 102000016938 Catalase Human genes 0.000 title claims abstract description 47
- 108010053835 Catalase Proteins 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 7
- 231100000444 skin lesion Toxicity 0.000 title claims abstract description 4
- 206010040882 skin lesion Diseases 0.000 title claims abstract description 4
- 208000002260 Keloid Diseases 0.000 claims abstract description 11
- 210000001117 keloid Anatomy 0.000 claims abstract description 11
- 230000003902 lesion Effects 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 230000001969 hypertrophic effect Effects 0.000 claims abstract description 7
- 231100000241 scar Toxicity 0.000 claims abstract description 7
- 208000032544 Cicatrix Diseases 0.000 claims abstract description 6
- 230000037387 scars Effects 0.000 claims abstract description 6
- 230000000699 topical effect Effects 0.000 claims abstract description 6
- 102000004190 Enzymes Human genes 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 17
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 240000007124 Brassica oleracea Species 0.000 claims description 7
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 7
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 7
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 7
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 7
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000000419 plant extract Substances 0.000 claims description 5
- 241000228245 Aspergillus niger Species 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 239000008176 lyophilized powder Substances 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 239000011859 microparticle Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 240000003291 Armoracia rusticana Species 0.000 claims description 3
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 3
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 claims description 3
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 3
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 3
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 240000005979 Hordeum vulgare Species 0.000 claims description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- 240000008042 Zea mays Species 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 3
- 229940040511 liver extract Drugs 0.000 claims description 3
- 235000011430 Malus pumila Nutrition 0.000 claims description 2
- 235000015103 Malus silvestris Nutrition 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 244000241257 Cucumis melo Species 0.000 claims 2
- 241000220225 Malus Species 0.000 claims 1
- 244000098338 Triticum aestivum Species 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 239000006071 cream Substances 0.000 abstract description 3
- 206010023330 Keloid scar Diseases 0.000 abstract description 2
- 239000000839 emulsion Substances 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 abstract description 2
- 206010020649 Hyperkeratosis Diseases 0.000 abstract 1
- 208000001126 Keratosis Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 description 18
- 206010016654 Fibrosis Diseases 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 230000036573 scar formation Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 241000219112 Cucumis Species 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 244000070406 Malus silvestris Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 206010004398 benign neoplasm of skin Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01006—Catalase (1.11.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Abstract
Description
病変に局所外部塗布するためのクリーム
プロピレングリコールジペラルゴエート 6%
プロピレングリコール 5%
ステアリン酸グリセリルエステル及びPEGステアレート 3%
ステアリン酸 3%
キサンタンガム 2%
エチレングリコール 1%
パルミチン酸セチル 1%
ワセリン 0.5%
アボカド油 1%
流動パラフィン 2%
トリエタノールアミン 0.67%
ソルビン酸カリウム 0.2%
防腐剤 0.3%
精油 (neroli)
SOD/CAT混合物 2%
水 qs
Claims (21)
- 炎症起源の皮膚病変の治療用の局所組成物を製造するための、スーパーオキシドジスムターゼとカタラーゼの混合物の使用。
- 病変が皮膚線維症、表皮角化症、ケロイド又は肥厚性瘢痕からなる群から選択されることを特徴とする請求項1に記載の使用。
- スーパーオキシドジスムターゼがリンゴ、ブロッコリ、芽キャベツ、キャベツもしくはメロン、(これらは、場合により遺伝子組換えであってもよい)、又はセイヨウワサビから抽出されることを特徴とする前記請求項のいずれか1項に記載の使用。
- スーパーオキシドジスムターゼがコムギ、トウモロコシ、ダイズ、及びオオムギから選択される酵素に富む穀類の種子又は芽から抽出されることを特徴とする請求項1又は2のいずれかに記載の使用。
- スーパーオキシドジスムターゼがバイオテクノロジーによって得られることを特徴とする請求項1及び2のいずれかに記載の使用。
- スーパーオキシドジスムターゼがサッカロマイセス・セレヴィシエ(Saccharomyces cerevisiae)の菌株から得られることを特徴とする前記請求項のいずれか1項に記載の使用。
- スーパーオキシドジスムターゼがウシ又はヒトの赤血球から抽出されるか、あるいは哺乳動物の肝臓から抽出されることを特徴とする請求項1及び2のいずれかに記載の使用。
- スーパーオキシドジスムターゼが大腸菌又は酵母による組換え合成によって製造されることを特徴とする請求項1又は2のいずれかに記載の使用。
- スーパーオキシドジスムターゼがバイオテクノロジーによって製造されるか、サッカロマイセス・セレヴィシエ(Saccharomyces cerevisiae)の天然菌株によって産生されることを特徴とする請求項1及び2のいずれかに記載の使用。
- カタラーゼが哺乳動物の肝臓の抽出物又はアスペルギルス・ニガー(Aspergillus niger)のような微生物の抽出物から得られることを特徴とする請求項1及び2のいずれかに記載の使用。
- カタラーゼが植物抽出物から得られることを特徴とする前記請求項のいずれか1項に記載の使用。
- カタラーゼが組換え合成によって得られることを特徴とする請求項1及び2のいずれか1項に記載の使用。
- カタラーゼ又はスーパーオキシドジスムターゼが、単独で又は混合物として、重合体に共有結合されるか又は複合されることを特徴とする前記請求項のいずれか1項に記載の使用。
- 重合体がポリエチレングリコール及び多糖類から選択されることを特徴とする前記請求項のいずれか1項に記載の使用。
- カタラーゼ又はスーパーオキシドジスムターゼが、単独で又は混合物として、カプセルに入れられるか又は高分子微粒子に混和されることを特徴とする前記請求項のいずれか1項に記載の使用。
- 高分子微粒子が架橋イオン性多糖及び/又は親水性重合体からなることを特徴とする前記請求項のいずれか1項に記載の使用。
- カタラーゼとスーパーオキシドジスムターゼが、単独で又は混合物として、凍結乾燥粉末の形態、結晶質懸濁物の形態又は硫酸アンモニウム懸濁物の形態であることを特徴とする前記請求項のいずれか1項に記載の使用。
- カタラーゼとスーパーオキシドジスムターゼが天然抽出物中に混合物として存在することを特徴とする前記請求項のいずれか1項に記載の使用。
- 天然抽出物がメロン抽出物、キャベツ抽出物又は哺乳動物肝臓抽出物から選択されることを特徴とする前記請求項のいずれか1項に記載の使用。
- SOD/CAT混合が14/2〜15/5の酵素活性比を、10 000〜16 000 IU/gのSOD酵素活性と共に示すことを特徴とする前記請求項のいずれか1項に記載の使用。
- カタラーゼ活性が約1500〜4000 IU/gであることを特徴とする前記請求項のいずれか1項に記載の使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2005/001837 WO2007000619A1 (fr) | 2005-06-28 | 2005-06-28 | Utilisation d’un melange de superoxyde dismutase et de catalase pour le traitement des lesions d’origine inflammatoire de la peau |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2008543967A true JP2008543967A (ja) | 2008-12-04 |
Family
ID=35134152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008518988A Pending JP2008543967A (ja) | 2005-06-28 | 2005-06-28 | 炎症性皮膚病変を治療するためのスーパーオキシドジスムターゼとカタラーゼとの混合物の使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090092591A1 (ja) |
EP (1) | EP1906992A1 (ja) |
JP (1) | JP2008543967A (ja) |
CN (1) | CN101247824A (ja) |
WO (1) | WO2007000619A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014527514A (ja) * | 2011-07-06 | 2014-10-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アルコールまたは有毒な代謝産物の代謝を標的としたナノカプセルによる酵素の経口送達法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010004367A1 (en) * | 2008-07-10 | 2010-01-14 | Life Science Investments Ltd | Use of a mixture of superoxide dismutase and catalase for treating pruritus and alleviating its symptoms |
KR101696504B1 (ko) | 2009-09-02 | 2017-01-13 | 액세스 비지니스 그룹 인터내셔날 엘엘씨 | 피부 복구용 조성물 및 방법 |
CN104774812A (zh) * | 2014-10-09 | 2015-07-15 | 湖南一九生物科技有限公司 | 玉米胚芽中提取超氧化物歧化酶的加工方法 |
CN107397689B (zh) * | 2017-07-12 | 2020-12-11 | 贵州九立德生物制药有限公司 | 一种用于皮肤护理的制剂及其制备方法 |
CN108042796B (zh) * | 2018-01-04 | 2021-11-30 | 江西华文科创文化发展有限公司 | 一种清除自由基的组合物及其制备方法与应用 |
FR3131196A1 (fr) | 2021-12-29 | 2023-06-30 | Lsi Silderma Ltd | Composition pour le traitement et/ou la prévention de la réapparition des vergetures rosées |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02273176A (ja) * | 1989-04-13 | 1990-11-07 | Seikagaku Kogyo Co Ltd | グリコサミノグリカンで修飾されたスーパーオキシドジスムターゼ及びその製造法 |
US5336493A (en) * | 1989-08-31 | 1994-08-09 | Poznansky Mark J | Superoxide dismutase-catalase conjugates |
JP2004256408A (ja) * | 2003-02-25 | 2004-09-16 | Nagase Chemtex Corp | 毛髪用洗浄剤及びこれを用いた毛髪の洗浄方法 |
WO2005046574A2 (en) * | 2003-07-30 | 2005-05-26 | Guthy-Renker Corporation | Compositions containing melon extracts |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5080886A (en) * | 1990-01-05 | 1992-01-14 | Sterling Drug Inc. | Pharmaceutical compositions for the prevention and treatment of oxidant injuries |
FR2716884B1 (fr) * | 1994-03-03 | 1996-10-04 | Bio Obtention Sc | Extrait protéique de cucumis melo à activité antioxydante et procédé de préparation, composition cosmétique ou pharmaceutique ou composition alimentaire contenant un tel extrait. |
ATE306903T1 (de) * | 1995-03-24 | 2005-11-15 | Genzyme Corp | Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren |
US5646025A (en) * | 1995-05-05 | 1997-07-08 | Novo Nordisk A/S | Scytalidium catalase gene |
US7468195B2 (en) * | 2000-06-09 | 2008-12-23 | Crawford Healthcare Limited | Skin treatment preparation |
-
2005
- 2005-06-28 WO PCT/IB2005/001837 patent/WO2007000619A1/fr active Application Filing
- 2005-06-28 EP EP05774360A patent/EP1906992A1/fr not_active Withdrawn
- 2005-06-28 US US11/988,053 patent/US20090092591A1/en not_active Abandoned
- 2005-06-28 CN CNA2005800514108A patent/CN101247824A/zh active Pending
- 2005-06-28 JP JP2008518988A patent/JP2008543967A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02273176A (ja) * | 1989-04-13 | 1990-11-07 | Seikagaku Kogyo Co Ltd | グリコサミノグリカンで修飾されたスーパーオキシドジスムターゼ及びその製造法 |
US5336493A (en) * | 1989-08-31 | 1994-08-09 | Poznansky Mark J | Superoxide dismutase-catalase conjugates |
JP2004256408A (ja) * | 2003-02-25 | 2004-09-16 | Nagase Chemtex Corp | 毛髪用洗浄剤及びこれを用いた毛髪の洗浄方法 |
WO2005046574A2 (en) * | 2003-07-30 | 2005-05-26 | Guthy-Renker Corporation | Compositions containing melon extracts |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014527514A (ja) * | 2011-07-06 | 2014-10-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アルコールまたは有毒な代謝産物の代謝を標的としたナノカプセルによる酵素の経口送達法 |
Also Published As
Publication number | Publication date |
---|---|
WO2007000619A1 (fr) | 2007-01-04 |
US20090092591A1 (en) | 2009-04-09 |
EP1906992A1 (fr) | 2008-04-09 |
CN101247824A (zh) | 2008-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Manela-Azulay et al. | Cosmeceuticals vitamins | |
US5698184A (en) | Compositions and methods for skin tanning and protection | |
JP3532244B2 (ja) | ムコ多糖類断片化抑制剤、活性酸素消去剤および化粧料 | |
KR101721845B1 (ko) | 피부 노화의 징후를 치료하기 위한 조성물 및 방법 | |
JP2008543967A (ja) | 炎症性皮膚病変を治療するためのスーパーオキシドジスムターゼとカタラーゼとの混合物の使用 | |
US6309656B1 (en) | Cosmetic and skin protective compositions | |
JP2001502685A (ja) | 感受性の皮膚の治療のための組成物の製造のための複合体の使用、製造方法および低アレルゲン性組成物 | |
Finosh et al. | Reactive oxygen species—Control and management using amphiphilic biosynthetic hydrogels for cardiac applications | |
US20070172431A1 (en) | Methods, systems and compositions for skin care | |
JPH05186324A (ja) | 美白化粧料 | |
JP2003081749A (ja) | 皮膚外用剤 | |
US7132118B2 (en) | Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance | |
JP4011634B2 (ja) | 左旋性アスコルビン酸(levogyre ascorbic acid(LAA))の安定化方法及び安定性LAA組成物 | |
KR20060020630A (ko) | 피지 관련 피부 질환의 국소 치료방법 | |
TWI691340B (zh) | 一種具抗老化、美白、抗過敏及細胞修護之紅藜萃取物 | |
US6630442B1 (en) | Reparatives for chemosurgery and laser (thermal) therapy | |
WO1986002556A1 (en) | A method for preventing or alleviating skin irritation using a formulation containing superoxide dismutase | |
JP5101769B2 (ja) | 生体の酸化防止または予防剤 | |
WO2010004367A1 (en) | Use of a mixture of superoxide dismutase and catalase for treating pruritus and alleviating its symptoms | |
US7468195B2 (en) | Skin treatment preparation | |
CN115350109A (zh) | 用于皮肤美白或改善皮肤皱纹的化妆料组合物及其制造方法 | |
JPH09291012A (ja) | 消炎性皮膚化粧料 | |
JPH11240817A (ja) | 美容パック | |
US4957740A (en) | Composition for preventing or alleviating skin irritation by formulations containing superoxide dismutase | |
JP2003095857A (ja) | 皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110309 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110609 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110711 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110719 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111012 |